American International Group Upped By $493,623 Its Douglas Emmett (DEI) Stake; Concordia International Corp. (CXRX) Covered By 4 Bullish Analysts Last Week

February 16, 2018 - By Adrian Erickson

Among 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Concordia Healthcare Corp. had 20 analyst reports since August 11, 2015 according to SRatingsIntel. RBC Capital Markets reinitiated it with “Outperform” rating and $86 target in Thursday, October 1 report. Mackie upgraded Concordia International Corp. (NASDAQ:CXRX) rating on Monday, October 19. Mackie has “Speculative Buy” rating and $42.50 target. The firm earned “Buy” rating on Tuesday, March 29 by Laurentian. The company was downgraded on Monday, August 15 by GMP Securities. The stock has “Reduce” rating by TD Securities on Wednesday, February 8. Canaccord Genuity maintained it with “Buy” rating and $95 target in Tuesday, August 11 report. The stock has “Neutral” rating by Goldman Sachs on Monday, August 15. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Sector Perform” rating given on Monday, November 30 by IBC. The rating was maintained by Scotia Capital on Friday, October 16 with “Sector Outperform”. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Underperformer” rating given on Monday, August 15 by IBC. See Concordia International Corp. (NASDAQ:CXRX) latest ratings:

American International Group Inc increased Douglas Emmett Inc (DEI) stake by 4.21% reported in 2017Q3 SEC filing. American International Group Inc acquired 12,657 shares as Douglas Emmett Inc (DEI)’s stock declined 2.71%. The American International Group Inc holds 313,215 shares with $12.35M value, up from 300,558 last quarter. Douglas Emmett Inc now has $7.11B valuation. The stock increased 0.55% or $0.2 during the last trading session, reaching $36.61. About 442,269 shares traded. Douglas Emmett, Inc. (NYSE:DEI) has risen 18.46% since February 16, 2017 and is uptrending. It has outperformed by 1.76% the S&P500.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $36.38 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

The stock increased 4.08% or $0.0284 during the last trading session, reaching $0.7249. About 22,763 shares traded. Concordia International Corp. (NASDAQ:CXRX) has declined 95.85% since February 16, 2017 and is downtrending. It has underperformed by 112.55% the S&P500.

Since September 21, 2017, it had 0 buys, and 1 insider sale for $3.90 million activity. $3.90M worth of Douglas Emmett, Inc. (NYSE:DEI) was sold by Emmett Dan A.

Among 17 analysts covering Douglas Emmett (NYSE:DEI), 5 have Buy rating, 2 Sell and 10 Hold. Therefore 29% are positive. Douglas Emmett had 54 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Robert W. Baird given on Wednesday, February 14. Barclays Capital maintained Douglas Emmett, Inc. (NYSE:DEI) on Wednesday, March 23 with “Underweight” rating. The stock of Douglas Emmett, Inc. (NYSE:DEI) earned “Buy” rating by Mizuho on Monday, September 21. The firm has “Underweight” rating by Barclays Capital given on Tuesday, January 30. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, November 9 report. The firm has “Buy” rating given on Monday, January 8 by Robert W. Baird. The stock has “Neutral” rating by DA Davidson on Thursday, May 18. Mizuho maintained the stock with “Hold” rating in Thursday, October 26 report. The firm earned “Neutral” rating on Monday, November 13 by Citigroup. The stock of Douglas Emmett, Inc. (NYSE:DEI) has “Hold” rating given on Tuesday, November 7 by BMO Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>